Published in Carcinogenesis on May 22, 2015
Low-Dose Mixture Hypothesis of Carcinogenesis Workshop: Scientific Underpinnings and Research Recommendations. Environ Health Perspect (2016) 0.78
Natural Compounds As Modulators of Non-apoptotic Cell Death in Cancer Cells. Curr Genomics (2017) 0.75
Hallmarks of cancer: the next generation. Cell (2011) 140.01
The hallmarks of cancer. Cell (2000) 113.05
The dendritic cell system and its role in immunogenicity. Annu Rev Immunol (1991) 23.09
Specific recruitment of regulatory T cells in ovarian carcinoma fosters immune privilege and predicts reduced survival. Nat Med (2004) 22.96
Cancer etiology. Variation in cancer risk among tissues can be explained by the number of stem cell divisions. Science (2015) 21.42
PD-1 and its ligands in tolerance and immunity. Annu Rev Immunol (2008) 19.24
Pharmaceuticals, hormones, and other organic wastewater contaminants in U.S. streams, 1999-2000: a national reconnaissance. Environ Sci Technol (2002) 10.93
Paradoxical roles of the immune system during cancer development. Nat Rev Cancer (2006) 10.57
Immunosuppressive networks in the tumour environment and their therapeutic relevance. Nat Rev Cancer (2005) 10.06
Crosstalk between cancer and immune cells: role of STAT3 in the tumour microenvironment. Nat Rev Immunol (2007) 9.37
Smoldering and polarized inflammation in the initiation and promotion of malignant disease. Cancer Cell (2005) 9.06
Association of cancer with AIDS-related immunosuppression in adults. JAMA (2001) 6.80
Hormones and endocrine-disrupting chemicals: low-dose effects and nonmonotonic dose responses. Endocr Rev (2012) 6.12
Mutation and cancer: a model for human carcinogenesis. J Natl Cancer Inst (1981) 5.59
Graft-versus-leukemia effect of donor lymphocyte transfusions in marrow grafted patients. Blood (1995) 5.34
Combining immunotherapy and targeted therapies in cancer treatment. Nat Rev Cancer (2012) 5.15
TGF-beta signaling in cancer--a double-edged sword. Trends Cell Biol (2001) 4.87
The concept of immunological surveillance. Prog Exp Tumor Res (1970) 4.76
Arginase I production in the tumor microenvironment by mature myeloid cells inhibits T-cell receptor expression and antigen-specific T-cell responses. Cancer Res (2004) 4.74
TGF-beta: a master of all T cell trades. Cell (2008) 4.60
H-2 compatibility is required for T-cell-mediated lysis of target cells infected with lymphocytic choriomeningitis virus. J Exp Med (1975) 4.16
High-dose granulocyte-macrophage colony-stimulating factor-producing vaccines impair the immune response through the recruitment of myeloid suppressor cells. Cancer Res (2004) 3.94
Immune infiltration in human tumors: a prognostic factor that should not be ignored. Oncogene (2009) 3.90
In vitro screening of environmental chemicals for targeted testing prioritization: the ToxCast project. Environ Health Perspect (2010) 3.84
Multistage carcinogenesis and the incidence of colorectal cancer. Proc Natl Acad Sci U S A (2002) 3.64
HIV infection is associated with an increased risk for lung cancer, independent of smoking. Clin Infect Dis (2007) 3.56
Donor leukocyte transfusions for treatment of recurrent chronic myelogenous leukemia in marrow transplant patients. Blood (1990) 3.50
A variety of environmentally persistent chemicals, including some phthalate plasticizers, are weakly estrogenic. Environ Health Perspect (1995) 3.47
Coley's toxins in perspective. Nature (1992) 3.40
Overexpression of PD-L1 significantly associates with tumor aggressiveness and postoperative recurrence in human hepatocellular carcinoma. Clin Cancer Res (2009) 3.39
Immune-induced epithelial to mesenchymal transition in vivo generates breast cancer stem cells. Cancer Res (2009) 3.30
Immune functions encoded by the natural killer gene complex. Nat Rev Immunol (2003) 3.21
Tolerance, DCs and tryptophan: much ado about IDO. Trends Immunol (2003) 3.18
Induction of lymphoidlike stroma and immune escape by tumors that express the chemokine CCL21. Science (2010) 3.08
Cancer immunoediting from immune surveillance to immune escape. Immunology (2007) 3.03
The strobilurin fungicides. Pest Manag Sci (2002) 2.81
A2A receptor signaling promotes peripheral tolerance by inducing T-cell anergy and the generation of adaptive regulatory T cells. Blood (2007) 2.69
Regulatory-T-cell inhibition versus depletion: the right choice in cancer immunotherapy. Nat Rev Cancer (2007) 2.68
Derangement of immune responses by myeloid suppressor cells. Cancer Immunol Immunother (2003) 2.65
Immune suppression in cancer: effects on immune cells, mechanisms and future therapeutic intervention. Semin Cancer Biol (2005) 2.64
TGF-beta and immune cells: an important regulatory axis in the tumor microenvironment and progression. Trends Immunol (2010) 2.61
The PD-1/PD-L1 axis modulates the natural killer cell versus multiple myeloma effect: a therapeutic target for CT-011, a novel monoclonal anti-PD-1 antibody. Blood (2010) 2.41
Deficiencies of GM-CSF and interferon gamma link inflammation and cancer. J Exp Med (2003) 2.36
Bisphenol A exposure during pregnancy disrupts glucose homeostasis in mothers and adult male offspring. Environ Health Perspect (2010) 2.35
Endocrine disrupting chemicals and disease susceptibility. J Steroid Biochem Mol Biol (2011) 2.28
Sargramostim for active Crohn's disease. N Engl J Med (2005) 2.24
B7-1 and B7-2 selectively recruit CTLA-4 and CD28 to the immunological synapse. Immunity (2004) 2.21
IL-6 regulates in vivo dendritic cell differentiation through STAT3 activation. J Immunol (2004) 2.12
Tumor-associated macrophages: effectors of angiogenesis and tumor progression. Biochim Biophys Acta (2009) 2.05
AIDS-related malignancies. Nat Rev Cancer (2002) 2.03
Integration of dosimetry, exposure, and high-throughput screening data in chemical toxicity assessment. Toxicol Sci (2011) 2.03
Immune escape as a fundamental trait of cancer: focus on IDO. Oncogene (2008) 1.97
CC chemokine ligand 2 (CCL2) promotes prostate cancer tumorigenesis and metastasis. Cytokine Growth Factor Rev (2009) 1.93
Indoleamine 2,3-dioxygenase in immune suppression and cancer. Curr Cancer Drug Targets (2007) 1.86
Risk assessment in immunotoxicology. I. Sensitivity and predictability of immune tests. Fundam Appl Toxicol (1992) 1.83
Systematic evaluation of genetic variants in the inflammation pathway and risk of lung cancer. Cancer Res (2007) 1.82
A stochastic carcinogenesis model incorporating genomic instability fitted to colon cancer data. Math Biosci (2003) 1.81
Cancer incidence and risk factors after solid organ transplantation. Int J Cancer (2009) 1.78
Immune-mediated dormancy: an equilibrium with cancer. J Leukoc Biol (2008) 1.75
Dr William Coley and tumour regression: a place in history or in the future. Postgrad Med J (2003) 1.72
Natural immunity to cancer in humans. Curr Opin Immunol (2010) 1.69
Defects in the human leukocyte antigen class I antigen processing machinery in head and neck squamous cell carcinoma: association with clinical outcome. Clin Cancer Res (2005) 1.68
Risk assessment of combined exposure to multiple chemicals: A WHO/IPCS framework. Regul Toxicol Pharmacol (2011) 1.67
2011: the immune hallmarks of cancer. Cancer Immunol Immunother (2011) 1.66
Immunoediting of cancers may lead to epithelial to mesenchymal transition. J Immunol (2006) 1.65
Update on EPA's ToxCast program: providing high throughput decision support tools for chemical risk management. Chem Res Toxicol (2012) 1.63
The toxins of William B. Coley and the treatment of bone and soft-tissue sarcomas. Iowa Orthop J (2006) 1.62
HER-2/neu antigen loss and relapse of mammary carcinoma are actively induced by T cell-mediated anti-tumor immune responses. Eur J Immunol (2007) 1.60
Epstein-Barr virus (EBV)-encoded small RNA is released from EBV-infected cells and activates signaling from Toll-like receptor 3. J Exp Med (2009) 1.60
Breaking patterns of environmentally influenced disease for health risk reduction: immune perspectives. Environ Health Perspect (2010) 1.58
Tumor immunoediting and immunosculpting pathways to cancer progression. Semin Cancer Biol (2007) 1.55
The classical Hodgkin's lymphoma microenvironment and its role in promoting tumour growth and immune escape. J Pathol (2010) 1.55
Interactions between effects of environmental chemicals and natural stressors: a review. Sci Total Environ (2009) 1.54
Post-transplant malignancy: the role of immunosuppression. Drug Saf (2000) 1.53
IL-2 immunotoxin therapy modulates tumor-associated regulatory T cells and leads to lasting immune-mediated rejection of breast cancers in neu-transgenic mice. J Immunol (2006) 1.53
Cancer incidence in New York State acquired immunodeficiency syndrome patients. Am J Epidemiol (2001) 1.51
Reversibility and persistence of di-2-ethylhexyl phthalate (DEHP)- and phenobarbital-induced hepatocellular changes in rodents. Toxicol Sci (2001) 1.47
An update of cancer incidence in the Agricultural Health Study. J Occup Environ Med (2010) 1.44
The impact of T-cell immunity on ovarian cancer outcomes. Immunol Rev (2008) 1.43
Reversal of Bcl-2-mediated resistance of the EW36 human B-cell lymphoma cell line to arsenite- and pesticide-induced apoptosis by PK11195, a ligand of the mitochondrial benzodiazepine receptor. Toxicol Sci (2003) 1.42
The effect of anti-VEGF therapy on immature myeloid cell and dendritic cells in cancer patients. Cancer Immunol Immunother (2008) 1.39
Modes of action and species-specific effects of di-(2-ethylhexyl)phthalate in the liver. Crit Rev Toxicol (2006) 1.37
Biologic and immunomodulatory events after CTLA-4 blockade with ticilimumab in patients with advanced malignant melanoma. Cancer (2006) 1.35
Hypoxia-mediated stimulation of carcinoma cell invasiveness via upregulation of urokinase receptor expression. Int J Cancer (1999) 1.34
The impact of bisphenol A and triclosan on immune parameters in the U.S. population, NHANES 2003-2006. Environ Health Perspect (2010) 1.34
Mechanisms of occupational asthma. J Allergy Clin Immunol (2009) 1.34
The multifaceted relationship between IL-10 and adaptive immunity: putting together the pieces of a puzzle. Cytokine Growth Factor Rev (2004) 1.34
Chronic effects of atrazine on estrus and mammary tumor formation in female Sprague-Dawley and Fischer 344 rats. J Toxicol Environ Health (1994) 1.33
Impact of environmental chemicals on key transcription regulators and correlation to toxicity end points within EPA's ToxCast program. Chem Res Toxicol (2010) 1.32
Epithelial-mesenchymal transition (EMT) induced by TNF-α requires AKT/GSK-3β-mediated stabilization of snail in colorectal cancer. PLoS One (2013) 1.31
Dual roles for immunity in gastrointestinal cancers. J Clin Oncol (2010) 1.31
De novo malignancies after liver transplantation: a major cause of late death. Liver Transpl (2001) 1.30
Incorporating human dosimetry and exposure into high-throughput in vitro toxicity screening. Toxicol Sci (2010) 1.30
Identification of alpha-enolase as an autoantigen in lung cancer: its overexpression is associated with clinical outcomes. Clin Cancer Res (2006) 1.29
Bisphenol A impairs the double-strand break repair machinery in the germline and causes chromosome abnormalities. Proc Natl Acad Sci U S A (2010) 1.29
Perinatal exposure to bisphenol A at reference dose predisposes offspring to metabolic syndrome in adult rats on a high-fat diet. Endocrinology (2011) 1.28
Oestrogenic and androgenic activity of triclosan in breast cancer cells. J Appl Toxicol (2008) 1.27
Chronic exposure to the herbicide, atrazine, causes mitochondrial dysfunction and insulin resistance. PLoS One (2009) 1.27
Atrazine-induced aromatase expression is SF-1 dependent: implications for endocrine disruption in wildlife and reproductive cancers in humans. Environ Health Perspect (2007) 1.27
Bisphenol A induces gene expression changes and proliferative effects through GPER in breast cancer cells and cancer-associated fibroblasts. Environ Health Perspect (2012) 1.27
Epilepsy treatment. Targeting LDH enzymes with a stiripentol analog to treat epilepsy. Science (2015) 1.92
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: the challenge ahead. Carcinogenesis (2015) 0.95
The effect of environmental chemicals on the tumor microenvironment. Carcinogenesis (2015) 0.91
Causes of genome instability: the effect of low dose chemical exposures in modern society. Carcinogenesis (2015) 0.86
Environmental immune disruptors, inflammation and cancer risk. Carcinogenesis (2015) 0.86
Metabolic reprogramming and dysregulated metabolism: cause, consequence and/or enabler of environmental carcinogenesis? Carcinogenesis (2015) 0.85
Functional properties of CD8(+) lymphocytes in patients with pleural plaque and malignant mesothelioma. J Immunol Res (2014) 0.84
The potential for chemical mixtures from the environment to enable the cancer hallmark of sustained proliferative signalling. Carcinogenesis (2015) 0.81
Assessing the carcinogenic potential of low-dose exposures to chemical mixtures in the environment: focus on the cancer hallmark of tumor angiogenesis. Carcinogenesis (2015) 0.78
Disruptive chemicals, senescence and immortality. Carcinogenesis (2015) 0.78
Disruptive environmental chemicals and cellular mechanisms that confer resistance to cell death. Carcinogenesis (2015) 0.77
Mechanisms of environmental chemicals that enable the cancer hallmark of evasion of growth suppression. Carcinogenesis (2015) 0.77
The Suppressed Induction of Human Mature Cytotoxic T Lymphocytes Caused by Asbestos Is Not due to Interleukin-2 Insufficiency. J Immunol Res (2016) 0.75